Naomi Nevler, Sunghye Cho, Katheryn A Q Cousins, Sharon Ash, Christopher A Olm, Sanjana Shellikeri, Galit Agmon, Carmen Gonzalez-Recober, Sharon X Xie, Megan S Barker, Masood Manoochehri, Corey T Mcmillan, David J Irwin, Lauren Massimo, Laynie Dratch, Gayathri Cheran, Edward D Huey, Stephanie A Cosentino, Vivianna M Van Deerlin, Mark Y Liberman, Murray Grossman
BACKGROUND AND OBJECTIVES: Clinical trials developing therapeutics for frontotemporal degeneration (FTD) focus on pathogenic variant carriers at preclinical stages. Objective, quantitative clinical assessment tools are needed to track stability and delayed disease onset. Natural speech can serve as an accessible, cost-effective assessment tool. We aimed to identify early changes in the natural speech of FTD pathogenic variant carriers before they become symptomatic. METHODS: In this cohort study, speech samples of picture descriptions were collected longitudinally from healthy participants in observational studies at the University of Pennsylvania and Columbia University between 2007 and 2020...
January 23, 2024: Neurology